Insider Selling: Exact Sciences Corporation (NASDAQ:EXAS) CFO Sells 5,846 Shares of Stock

Exact Sciences Corporation (NASDAQ:EXAS) CFO Jeffrey Thomas Elliott sold 5,846 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the transaction, the chief financial officer now owns 19,861 shares of the company’s stock, valued at approximately $782,722.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Exact Sciences Corporation (EXAS) traded up 1.09% during mid-day trading on Friday, hitting $37.87. 1,039,106 shares of the stock traded hands. The firm’s 50-day moving average is $38.05 and its 200-day moving average is $29.56. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $42.18. The company’s market cap is $4.51 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The business had revenue of $57.65 million during the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. Equities research analysts expect that Exact Sciences Corporation will post ($1.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Exact Sciences Corporation (NASDAQ:EXAS) CFO Sells 5,846 Shares of Stock” was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/19/insider-selling-exact-sciences-corporation-nasdaqexas-cfo-sells-5846-shares-of-stock-updated-updated.html.

Several institutional investors have recently bought and sold shares of the stock. Neuberger Berman Group LLC purchased a new position in Exact Sciences Corporation during the first quarter worth $6,391,000. Nationwide Fund Advisors raised its position in Exact Sciences Corporation by 52.1% in the first quarter. Nationwide Fund Advisors now owns 149,167 shares of the medical research company’s stock worth $3,523,000 after buying an additional 51,085 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Exact Sciences Corporation during the fourth quarter valued at approximately $758,000. UBS Group AG raised its position in shares of Exact Sciences Corporation by 32.1% in the first quarter. UBS Group AG now owns 108,305 shares of the medical research company’s stock valued at $2,558,000 after buying an additional 26,309 shares during the period. Finally, Norges Bank bought a new position in shares of Exact Sciences Corporation during the fourth quarter valued at approximately $25,200,000. 85.44% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Vetr downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $38.66 price objective for the company. in a report on Thursday, August 3rd. Canaccord Genuity reiterated a “buy” rating and issued a $45.00 price objective (up previously from $42.00) on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Bank of America Corporation reiterated a “buy” rating on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Finally, Roth Capital increased their price objective on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $40.51.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply